Market Herald logo

Subscribe

Be the first with the news that moves the market
  • Biotechnology company WPD Pharmaceuticals (WBIO) plans to start Phase I of a clinical trial for treating child brain cancer. 
  • The trial will test the use of the drug Berubicin as a treatment for pediatric brain tumours.
  • Phase I of the trial will take place at the Children’s Memorial Health Institute in Poland.
  • The trial will be conducted in collaboration with biotechnology company CNS Pharmaceuticals.
  • WPD’s share price is down 1.47 per cent, with shares currently trading at $1.34 apiece.

Biotechnology and pharmaceutical company WPD Pharmaceuticals (WBIO) has announced plans to initiate Phase I of a clinical trial.

The trial will test the use of the drug Berubicin for treating brain cancer in children. 

The trial will be conducted in collaboration with biotechnology company CNS Pharmaceuticals, who WPD currently has a sublicense agreement with. Under the terms of the agreement, WPD has commercial rights (in a limited territory) to Berubicin.

Subsequently, WPD been granted $6 million from the EU/Polish National Centre for Research and Development. The money from the grant will be used to fund the upcoming Phase I trial. 

Phase I of the trial is expected to take place at the Children’s Memorial Health Institute in Warsaw, the largest and most well-equipped pediatric hospital in Poland.

WPD and CNS are currently working with experts at the hospital to complete the documentation for the study.

Chief Executive Officer of WPD, Mariusz Olejniczak, spoke about the impending trial. “We are very excited to initiate a Phase I clinical trial and further expand the scope of Berubicin. We look forward to our collaboration with CNS and Children’s Memorial in Poland, to initiate what we believe to be the first investigation for a unique topoisomerase II inhibitor that appears to be able to cross the blood-brain barrier in pediatric brain tumours.”

WPD’s share price is down 1.47 per cent, with shares currently trading at $1.34 apiece at 11:08am EST.

More From The Market Herald
Featured Video Play Icon

" OpSens (TSX:OPS) announces first SavvyWire procedure in the U.S.

OpSens (OPS) is announcing the first SavvyWire procedure in the U.S.

" Lobe Sciences (CSE:LOBE) incorporates Australian subsidiary for psilocin trials

Lobe Sciences (LOBE) has incorporated its wholly-owned Australian subsidiary to facilitate three or more clinical trials.
Featured Video Play Icon

" Rapid Dose Therapeutics (CSE:DOSE) to supply leading gas and convenience store retailer

Rapid Dose (DOSE) has signed a supplier agreement with a leading gas and convenience store retailer.

" NervGen Pharma (TSXV:NGEN) announces leadership changes

NervGen Pharma Corp. (NGEN) has announced several leadership changes.